How I Treat High-Risk Patients with Essential Thrombocythemia or Polycythemia Vera
Upon viewing this session, you will be able to identify risk stratify patients with Essential Thrombocythemia and Polycythemia Vera (ET/PV), recognize hydroxyurea intolerance and resistance, appreciate the potential role of interferon-α in the treatment of ET/PV, and identify appropriate patients with PV for JAK2 inhibitor therapy.
John Mascarenhas, MD, Mount Sinai School of Medicine
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members